![Katie Flaherty](/newimages/person-profile/2022a/katie-flaherty.x62057b61.jpeg?w=167&h=160&crop=160,160,4,0&f=webp)
Biography
Research
![Schurich group Banner Image](/newimages/folsm/hero-banner/sims/schurich-group-banner-image.x7c2e869c.png?w=1261&h=440&crop=780,440,329,0&width=380&height=215&fit=crop&f=webp)
Schurich Group
The Schurich Lab studies the function of human T cells, with a focus on T cell metabolism to understand how T cells fuel their extraordinary effector capacity.
![car mechanics RG thumbnail](/newimages/folsm/hero-banner/scps/car-mechanics-rg-thumbnail.x51fbea40.png?width=380&height=215&fit=crop&f=webp)
CAR Mechanics Group
The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.
Research
![Schurich group Banner Image](/newimages/folsm/hero-banner/sims/schurich-group-banner-image.x7c2e869c.png?w=1261&h=440&crop=780,440,329,0&width=380&height=215&fit=crop&f=webp)
Schurich Group
The Schurich Lab studies the function of human T cells, with a focus on T cell metabolism to understand how T cells fuel their extraordinary effector capacity.
![car mechanics RG thumbnail](/newimages/folsm/hero-banner/scps/car-mechanics-rg-thumbnail.x51fbea40.png?width=380&height=215&fit=crop&f=webp)
CAR Mechanics Group
The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.